Chhibber-Goel Jyoti, Gopinathan Sreehari, Sharma Amit
Molecular Medicine Group, International Center for Genetic Engineering and Biotechnology, New Delhi, India.
Gut Pathog. 2021 Feb 25;13(1):14. doi: 10.1186/s13099-021-00407-7.
COVID-19 is an acute respiratory distress syndrome and is often accompanied by gastrointestinal symptoms. The SARS-CoV-2 has been traced not only in nasopharyngeal and mid-nasal swabs but also in stool and rectal swabs of COVID-19 patients. The gut microbiota is important for an effective immune response as it ensures that unfavorable immune reactions in lungs and other vital organs are regulated. The human gut-lung microbiota interplay provides a framework for therapies in the treatment and management of several pulmonary diseases and infections. Here, we have collated data from COVID-19 studies, which suggest that bacterial co-infections as well as the gut-lung cross talk may be important players in COVID-19 disease prognosis. Our analyses suggests a role of gut microbiome in pathogen infections as well as in an array of excessive immune reactions during and post COVID-19 infection recovery period.
新冠病毒病是一种急性呼吸窘迫综合征,常伴有胃肠道症状。严重急性呼吸综合征冠状病毒2不仅在鼻咽拭子和中鼻拭子中被检测到,在新冠病毒病患者的粪便和直肠拭子中也被检测到。肠道微生物群对有效的免疫反应很重要,因为它能确保调节肺部和其他重要器官中不良的免疫反应。人体肠道-肺部微生物群的相互作用为多种肺部疾病和感染的治疗与管理提供了治疗框架。在此,我们整理了来自新冠病毒病研究的数据,这些数据表明细菌合并感染以及肠道-肺部相互作用可能是新冠病毒病疾病预后的重要因素。我们的分析表明肠道微生物群在病原体感染以及新冠病毒病感染恢复期及之后一系列过度免疫反应中发挥作用。